Literature DB >> 15175032

BP230- and BP180-specific auto-antibodies in bullous pemphigoid.

Sybille Thoma-Uszynski1, Wolfgang Uter, Susanne Schwietzke, Silke C Hofmann, Thomas Hunziker, Philippe Bernard, Regina Treudler, Christos C Zouboulis, Gerold Schuler, Luca Borradori, Michael Hertl.   

Abstract

Bullous pemphigoid is a subepidermal blistering disease associated with auto-antibodies (auto-ab) to BP180 and BP230. We developed ELISAs utilizing baculovirus-encoded recombinant proteins of BP230 and BP180 and studied their diagnostic and prognostic values by assessing the profile of the auto-ab response in 127 patients with BP. 39 patients had focal involvement, whereas 88 had generalized disease; 51 individuals served as controls. The results indicate: (1) BP180 IgG reactivity was associated with an overall sensitivity of 0.953 and specificity of 0.940; (2) 105 of 127 BP patients also displayed BP230 auto-reactivity, the global diagnostic performance of which, however, was moderate compared to BP180-auto-reactivity (sensitivity 0.815 vs 0.953, specificity 0.648 vs 0.940); (3) 101 patients (79.5%) had concordant BP180 and BP230 reactivity; (4) the association between the presence of BP230 auto-reactivity and focal involvement was stronger than in generalized disease (odds ratio (OR) 17.7 vs 10.2), independently from BP180 auto-ab profile; (5) correlation of total IgG with IgG1 and IgG4 was variable for both BP180 and BP230. Collectively, the global diagnostic properties of the BP180-ELISA outperform those of the BP230-ELISA. Presence of BP230 auto-reactivity, however, supports the diagnosis of BP and might be indicative for the extent of the disease.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15175032     DOI: 10.1111/j.0022-202X.2004.22603.x

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  22 in total

1.  [A severe course of bullous pemphigoid in a young man].

Authors:  S Eigelshoven; D Bruch-Gerharz; E Enderlein; T Ruzicka; A S Büchau; M Hertl; J Reifenberger; K-W Schulte
Journal:  Hautarzt       Date:  2006-04       Impact factor: 0.751

2.  Assessment of the Prevalence of Mucosal Involvement in Bullous Pemphigoid.

Authors:  Khalaf Kridin; Reuven Bergman
Journal:  JAMA Dermatol       Date:  2019-02-01       Impact factor: 10.282

Review 3.  Mechanisms of Disease: Pemphigus and Bullous Pemphigoid.

Authors:  Christoph M Hammers; John R Stanley
Journal:  Annu Rev Pathol       Date:  2016-02-22       Impact factor: 23.472

4.  Localised bullous pemphigoid overlying knee arthroplasty: a diagnostic challenge.

Authors:  Adam Truss; Stylianos Papalexandris; Susan Gardner; Robert Harvey
Journal:  BMJ Case Rep       Date:  2019-04-05

5.  Membranous glomerulonephropathy in a patient with bullous pemphigoid.

Authors:  Misa Ikeda; Hirokazu Honda; Naoto Kobayashi; Shoko Onuma; Kei Matsumoto; Tadao Akizawa; Yutaka Yamaguchi; Takanori Shibata
Journal:  CEN Case Rep       Date:  2016-11-04

Review 6.  Clinical and serological responses following plasmapheresis in bullous pemphigoid: two case reports and a review of the literature.

Authors:  Brian Chang; Ashok Tholpady; Richard S P Huang; Elena Nedelcu; Yu Bai
Journal:  Blood Transfus       Date:  2014-04       Impact factor: 3.443

Review 7.  T cell control in autoimmune bullous skin disorders.

Authors:  Michael Hertl; Rüdiger Eming; Christian Veldman
Journal:  J Clin Invest       Date:  2006-05       Impact factor: 14.808

8.  Bullous Pemphigoid: A Spontaneous Presentation in a Patient With Chronic Kidney Disease.

Authors:  Brett Brazen; Ariel Kidron; Zakaria Sheikh; Vikeerna Kamatgi; Sann Htoo
Journal:  Cureus       Date:  2022-06-10

9.  Diagnosis and clinical severity markers of bullous pemphigoid.

Authors:  Enno Schmidt; Detlef Zillikens
Journal:  F1000 Med Rep       Date:  2009-02-24

10.  Usefulness of Enzyme-linked Immunosorbent Assay Using Recombinant BP180 and BP230 for Serodiagnosis and Monitoring Disease Activity of Bullous Pemphigoid.

Authors:  Eui Hyung Lee; Yeon Hee Kim; Sinyoung Kim; Song-Ee Kim; Soo-Chan Kim
Journal:  Ann Dermatol       Date:  2012-02-02       Impact factor: 1.444

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.